<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39466467</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1573-4978</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Molecular biology reports</Title><ISOAbbreviation>Mol Biol Rep</ISOAbbreviation></Journal><ArticleTitle>Characterization of the viral genome of Omicron variants of SARS-CoV-2 circulating in Tripura, a remote frontier state in Northeastern India.</ArticleTitle><Pagination><StartPage>1100</StartPage><MedlinePgn>1100</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11033-024-10048-z</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">From 2020, with advent of COVID-19 pandemic, Tripura has experienced SARS-CoV-2 viral evolution in accordance with other parts of India. Since January 2022, the Omicron variant of SARS-CoV-2 virus became the predominant lineage circulating in India and neighboring countries. This study characterizes the viral genome of the omicron variant circulating in the state since its inception to June, 2023.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">The current study was performed on nasopharyngeal and oropharyngeal samples received from the various departments of AGMC, as well as eight district hospitals from Tripura. The positive samples with a cycle threshold value of 25 or less for the E and/or N gene were considered for whole genome sequencing using Illumina Miseq NGS platform. Majority of the sequences belonged to Clade 21 L, with BA.5.2 being the major sub variant detected during the study period. Majority of the mutations were detected in the Spike protein region, including L24-, P25-, P26-, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, S477N, T478K, Q498R, Y505H, Q954H and N969K. All the sequences uniquely showed the mutations A27S and G142D in N terminal domain in Spike protein, not being reported from other Indian sequences like BA.5 variants. T9I, A63T and P13L were major substitutions in E, M and N protein regions respectively. Escape of mutants from vaccine induced immunity was mostly observed in BA.2 sub variants, majority endowed with the triplet mutation of K417N + E484K + N501Y.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The current study indicates that Omicron variants circulating in the state of Tripura is comparable to other regions of India and the neighbouring country of Bangladesh. Genetic mutations increasing viral transmissibility have been identified in the circulating viral genomes.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Nature B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chakrabarti</LastName><ForeName>Ankan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2882-9606</Identifier><AffiliationInfo><Affiliation>Medical Research Scientist, Viral Research &amp; Diagnostic Laboratory, Agartala Government Medical College &amp; GBP Hospital, Agartala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majumder</LastName><ForeName>Saikat</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1317-8070</Identifier><AffiliationInfo><Affiliation>Medical Research Scientist, Viral Research &amp; Diagnostic Laboratory, Agartala Government Medical College &amp; GBP Hospital, Agartala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Apurba</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0541-8241</Identifier><AffiliationInfo><Affiliation>Medical Research Scientist, Viral Research &amp; Diagnostic Laboratory, Agartala Government Medical College &amp; GBP Hospital, Agartala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majumdar</LastName><ForeName>Tapan</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5375-133X</Identifier><AffiliationInfo><Affiliation>Medical Research Scientist, Viral Research &amp; Diagnostic Laboratory, Agartala Government Medical College &amp; GBP Hospital, Agartala, India. drtapan1@rediffmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Mol Biol Rep</MedlineTA><NlmUniqueID>0403234</NlmUniqueID><ISSNLinking>0301-4851</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016679" MajorTopicYN="Y">Genome, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073336" MajorTopicYN="N">Whole Genome Sequencing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009305" MajorTopicYN="N">Nasopharynx</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Mutation</Keyword><Keyword MajorTopicYN="N">Next generation sequencing</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">qRT-PCR</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>12</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39466467</ArticleId><ArticleId IdType="doi">10.1007/s11033-024-10048-z</ArticleId><ArticleId IdType="pii">10.1007/s11033-024-10048-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO) (2021) Listings of WHO’s response to COVID-19. (accessed 4 February 2023), https://www.who.int/news/item/29-06-2020-covidtimeline</Citation></Reference><Reference><Citation>Rana R, Kant R, Huirem RS, Bohra D, Ganguly NK (2022) Omicron variant: Current insights and future directions. Microbiol Res;265:127204. https://doi.org/10.1016/j.micres.2022.127204</Citation></Reference><Reference><Citation>Chakraborti S, Gill J, Goswami R, Kumar S, Chandele A, Sharma A (2022) Structural profiles of SARS-CoV-2 variants in India. Curr Microbiol 80(1):1. https://doi.org/10.1007/s00284-022-03094-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-022-03094-y</ArticleId><ArticleId IdType="pubmed">36414797</ArticleId><ArticleId IdType="pmc">9684916</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Liu Y, Ziarnik M, Cao Y, Zhang F, Im W (2022) Binding of human ACE2 and RBD of Omicron enhanced by unique interaction patterns among SARS-CoV-2 variants of concern. https://doi.org/10.1101/2022.01.24.477633 . bioRxiv.</Citation></Reference><Reference><Citation>Shrestha L, Foster C, Rawlinson W, Tedla N, Bull R (2022) Evolution of the SARS-CoV-2omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev Med Virol 32:e2381. https://doi.org/10.1002/rmv.2381</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2381</ArticleId><ArticleId IdType="pubmed">35856385</ArticleId><ArticleId IdType="pmc">9349777</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO, Tracking, SARS-CoV-2 Variants (2022). Available online at: https://www.who.int/activities/tracking-SARSCoV-2-variants (accessed 4 February, 2023)</Citation></Reference><Reference><Citation>Singh P, Sharma K, Shaw D, Bhargava A, Negi SS (2023) Mutational characterization of Omicron SARS-CoV-2 lineages circulating in Chhattisgarh, a central state of India. Front Med 9. https://doi.org/10.3389/fmed.2022.1082846</Citation></Reference><Reference><Citation>Mohapatra R, Kandi V, Sarangi A, Verma S, Tuli H, Chakraborty S et al (2022) The recently emerged BA.4 and BA.5 lineages of omicron and their global health concerns amid the ongoing wave of COVID-19 pandemic–correspondence. Int J Surg 103:106698. https://doi.org/10.1016/j.ijsu.2022.106698</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2022.106698</ArticleId><ArticleId IdType="pubmed">35690362</ArticleId><ArticleId IdType="pmc">9176102</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracked lineages in India- available at https://outbreak.info/location-reports (accessed on 22.09.2024)</Citation></Reference><Reference><Citation>Illumina COVIDSeq RUO Kits. Reference Guide 1000000126053 v08. Illumina (2022) https://support.illumina.com/content/dam/illumina-support/documents/documentation/chemistry_documentation/Illumina-COVIDSeq-Test/illumina-covidseq-ruo-kits-reference-guide-1000000126053-08.pdf . Accessed on 07.10.2023</Citation></Reference><Reference><Citation>MiSeq System. Denature and Dilute Libraries Guide. Document # 15039740 v10. Illumina (2019) https://support.illumina.com/content/dam/illumina-support/documents/documentation/system_documentation/miseq/miseq-denature-dilute-libraries-guide-15039740-10.pdf . Accessed on 07.10.2023</Citation></Reference><Reference><Citation>MiSeq System Guide. Document # 15027617 v05 Material # 20000262. Illumina (2019) https://support.illumina.com/content/dam/illumina-support/documents/documentation/system_documentation/miseq/miseq-system-guide-for-local-run-manager-15027617-05.pdf . Accessed on 07.10.2023</Citation></Reference><Reference><Citation>Turakhia Y, Thornlow B, Hinrichs AS et al (2021) Ultrafast Sample placement on existing tRees (UShER) enables real-time phylogenetics for the SARS-CoV-2 pandemic. Nat Genet 53:809–816. https://doi.org/10.1038/s41588-021-00862-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00862-7</ArticleId><ArticleId IdType="pubmed">33972780</ArticleId><ArticleId IdType="pmc">9248294</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh UB, Deb S, Rani L, Bhardwaj D, Gupta R, Kabra M et al (2023) Genomic surveillance of SARS-CoV-2 upsurge in India due to Omicron sub-lineages BA.2.74, BA.2.75 and BA.2.76. Lancet Reg Health Southeast Asia 100148. https://doi.org/10.1016/j.lansea.2023.100148</Citation></Reference><Reference><Citation>Bhoyar RC, Senthivel V, Jolly B et al (2021) An optimized, Amplicon-based approach for sequencing of SARS-CoV-2 from patient samples using COVIDSeq assay on Illumina MiSeq sequencing platforms. STAR Protoc 2(3):100755. https://doi.org/10.1016/j.xpro.2021.100755</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xpro.2021.100755</ArticleId><ArticleId IdType="pubmed">34368787</ArticleId><ArticleId IdType="pmc">8326003</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman K, Shete AM, Mishra SK, Kumar A, Reddy MM, Sahay RR et al (2022) Omicron BA.2 lineage predominance in severe acute respiratory syndrome coronavirus 2 positive cases during the third wave in North India. Front Med (Lausanne) 9:955930. https://doi.org/10.3389/fmed.2022.955930</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.955930</ArticleId><ArticleId IdType="pubmed">36405589</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P, Sharma K, Shaw D, Bhargava A, Negi SS (2023) Mutational characterization of Omicron SARS-CoV-2 lineages circulating in Chhattisgarh, a central state of India. Front Med (Lausanne) 9:1082846. https://doi.org/10.3389/fmed.2022.1082846</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1082846</ArticleId><ArticleId IdType="pubmed">36755883</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin SZ, Sathi FA, Nooruzzaman M, Parvin R (2023) Molecular insights into the SARS-CoV-2 Omicron variant from Bangladesh suggest diverse and continuous evolution. Virology 587:109882. https://doi.org/10.1016/j.virol.2023.109882</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2023.109882</ArticleId><ArticleId IdType="pubmed">37757731</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty C, Bhattacharya M, Sharma AR, Mallik B (2022) Omicron (B.1.1.529) - a new heavily mutated variant: mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. Int J Biol Macromol 219:980–997. https://doi.org/10.1016/j.ijbiomac.2022.07.254</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2022.07.254</ArticleId><ArticleId IdType="pubmed">35952818</ArticleId><ArticleId IdType="pmc">9359758</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty C, Saha A, Bhattacharya M, Dhama K, Agoramoorthy G (2023) Natural selection of the D614G mutation in SARS-CoV-2 Omicron (B.1.1.529) variant and its subvariants. Mol Ther Nucleic Acids 31:437–439. https://doi.org/10.1016/j.omtn.2023.01.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2023.01.013</ArticleId><ArticleId IdType="pubmed">36817724</ArticleId><ArticleId IdType="pmc">9923361</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA (2022) Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev Med Virol 32(5):e2381. https://doi.org/10.1002/rmv.2381</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2381</ArticleId><ArticleId IdType="pubmed">35856385</ArticleId><ArticleId IdType="pmc">9349777</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha KM, Targeting the Variants of COVID-19 via the Unlimited Approach (2023) Indian J Microbiol 63(1):152–154. https://doi.org/10.1007/s12088-023-01057-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12088-023-01057-w</ArticleId><ArticleId IdType="pubmed">36714462</ArticleId><ArticleId IdType="pmc">9854402</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccinate India, Tripura https://vaccinate-india.in/state/33 . Accessed on 30.04.2024</Citation></Reference><Reference><Citation>Sabbatucci M, Vitiello A, Clemente S, Zovi A, Boccellino M, Ferrara F et al (2023) Omicron variant evolution on vaccines and monoclonal antibodies. Inflammopharmacology 31(4):1779–1788. https://doi.org/10.1007/s10787-023-01253-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-023-01253-6</ArticleId><ArticleId IdType="pubmed">37204696</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A et al (2022) Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185(14):2422–2433e13. https://doi.org/10.1016/j.cell.2022.06.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.005</ArticleId><ArticleId IdType="pubmed">35772405</ArticleId><ArticleId IdType="pmc">9181312</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SB, Khan M, Chiliveri SC, Hu X, Irvin P, Leek M et al (2023) SARS-CoV-2 omicron variants harbor spike protein mutations responsible for their attenuated fusogenic phenotype. Commun Biol 6(1):556. https://doi.org/10.1038/s42003-023-04923-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-023-04923-x</ArticleId><ArticleId IdType="pubmed">37225764</ArticleId><ArticleId IdType="pmc">10206564</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang K, Wang C, Kreutzberger AJB, White KI, Pfuetzner RA, Esquivies L et al (2023) Structure-based design of a SARS-CoV-2 Omicron-specific inhibitor. Proc Natl Acad Sci U S A 120(13):e2300360120. https://doi.org/10.1073/pnas.2300360120</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2300360120</ArticleId><ArticleId IdType="pubmed">36940324</ArticleId><ArticleId IdType="pmc">10068829</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito A, Tamura T, Zahradnik J, Deguchi S, Tabata K, Anraku Y et al (2022) Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. Cell Host Microbe 30(11):1540–1555e15. https://doi.org/10.1016/j.chom.2022.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.10.003</ArticleId><ArticleId IdType="pubmed">36272413</ArticleId><ArticleId IdType="pmc">9578327</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Song W, Wang L, Liu P, Yue C, Jian F et al (2022) Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. Cell Host Microbe 30(11):1527–1539e5. https://doi.org/10.1016/j.chom.2022.09.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.09.018</ArticleId><ArticleId IdType="pubmed">36270286</ArticleId><ArticleId IdType="pmc">9531665</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid M, Jawed A, Mandal RK, Dailah HG, Janahi EM, Dhama K et al (2021) Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies. Eur Rev Med Pharmacol Sci 25(18):5857–5864. https://doi.org/10.26355/eurrev_202109_26805</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202109_26805</ArticleId><ArticleId IdType="pubmed">34604978</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh UB, Deb S, Rani L, Bhardwaj D, Gupta R, Kabra M et al (2023) Genomic surveillance of SARS-CoV-2 upsurge in India due to Omicron sub-lineages BA.2.74, BA.2.75 and BA.2.76. Lancet Reg Health Southeast Asia 11:100148. https://doi.org/10.1016/j.lansea.2023.100148</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lansea.2023.100148</ArticleId><ArticleId IdType="pubmed">36643851</ArticleId><ArticleId IdType="pmc">9832050</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvavinayagam ST, Karishma SJ, Hemashree K, Yong YK, Suvaithenamudhan S, Rajeshkumar M et al (2023) Clinical characteristics and novel mutations of omicron subvariant XBB in Tamil Nadu, India - a cohort study. Lancet Reg Health Southeast Asia 19:100272. https://doi.org/10.1016/j.lansea.2023.100272</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lansea.2023.100272</ArticleId><ArticleId IdType="pubmed">38076717</ArticleId><ArticleId IdType="pmc">10709680</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal S, Rana G, Singhal S, Singh M, Kumar M, Thaledi S et al (2024) Characterization and distribution of Sars-CoV-2 Omicron variant and its sub-lineages in Uttarakhand using Next Generation sequencing: a retrospective study. J Pure Appl Microbiol 18(1):682–695. https://doi.org/10.22207/JPAM.18.1.57</Citation><ArticleIdList><ArticleId IdType="doi">10.22207/JPAM.18.1.57</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvavinayagam ST, Sankar S, Yong YK, Murugesan A, Suvaithenamudhan S, Hemashree K et al (2024) Emergence of SARS-CoV-2 omicron variant JN.1 in Tamil Nadu, India - Clinical characteristics and novel mutations. Sci Rep 14(1):17476. https://doi.org/10.1038/s41598-024-68678-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-68678-z</ArticleId><ArticleId IdType="pubmed">39080396</ArticleId><ArticleId IdType="pmc">11289243</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A, Zia T, Suleman M et al (2021) Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data. J Cell Physiol 236(10):7045–7057. https://doi.org/10.1002/jcp.30367</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.30367</ArticleId><ArticleId IdType="pubmed">33755190</ArticleId><ArticleId IdType="pmc">8251074</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey WT, Carabelli AM, Jackson B et al (2021) SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19(7):409–424. https://doi.org/10.1038/s41579-021-00573-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId><ArticleId IdType="pmc">8167834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Pan X, Ji H, Zuo X, Xiao GF, Li J et al (2023) Impact of SARS-CoV-2 envelope protein mutations on the pathogenicity of Omicron XBB. Cell Discov 9(1):80. https://doi.org/10.1038/s41421-023-00575-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-023-00575-7</ArticleId><ArticleId IdType="pubmed">37507399</ArticleId><ArticleId IdType="pmc">10382526</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsuwairi FA, Alsaleh AN, Alsanea MS, Al-Qahtani AA, Obeid D, Almaghrabi RS et al (2023) Association of SARS-CoV-2 Nucleocapsid Protein Mutations with Patient Demographic and Clinical Characteristics during the Delta and Omicron Waves. Microorganisms;11(5):1288. https://doi.org/10.3390/microorganisms11051288</Citation></Reference><Reference><Citation>Wu JL, Kuan II, Guo JY, Hsu WC, Tang WC, Chan HJ et al (2023) SARS-CoV-2 N protein mediates intercellular nucleic acid dispersion, a feature reduced in Omicron. iScience;26(2):105995. https://doi.org/10.1016/j.isci.2023.105995</Citation></Reference><Reference><Citation>Bianchi M, Borsetti A, Ciccozzi M, Pascarella S (2021) SARS-Cov-2 ORF3a: mutability and function. Int J Biol Macromol 170:820–826. https://doi.org/10.1016/j.ijbiomac.2020.12.142</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2020.12.142</ArticleId><ArticleId IdType="pubmed">33359807</ArticleId><ArticleId IdType="pmc">7836370</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehrer T, Cupic A, Ye C, Yildiz S, Bouhaddou M, Crossland NA et al (2023) Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis. Cell Host Microbe. 2023;31(10):1668–1684.e12. https://doi.org/10.1016/j.chom.2023.08.003</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>